Hepatitis C future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Assistant Editor-In-Chief: Nina Axiotakis [2]

Overview

Several investigational drugs are being tested for use in hepatitis C such as danoprevir, asunaprevir, vaniprevir, and ledipasvir among others.

Future Or Investigational Therapies

Several investigational drugs are being tested for use in hepatitis C. These agents focus on proteins essential for viral replication. The table below summarizes the agents currently being investigated.

Name	Alternative	Mechanism of Action
Danoprevir^[1]	RG7227/ITMN-191	Inhibitor of the HCV NS3/4A serine protease
Asunaprevir^[2]	BMS-650032	Inhibitor of the HCV NS3/4A serine protease
Vaniprevir^[3]	MK-7009	Inhibitor of the HCV NS3/4A serine protease
Daclatasvir^[4]	BMS-790052	Inhibitor of the HCV non-structural protein NS5A
Mericitabine^[5]	RG7128	Inhibitor of the HCV NS5B polymerase
Ledipasvir^[6]	GS-5885	Inhibitor of the HCV non-structural protein NS5A
Faldaprevir^[7]	BI-2010335	Protease inhibitor

References

↑ Jiang Y, Andrews SW, Condroski KR, Buckman B, Serebryany V, Wenglowsky S; et al. (2014). “Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease”. J Med Chem. 57 (5): 1753–69. doi:10.1021/jm400164c. PMID 23672640.
↑ Eley T, He B, Chang I, Colston E, Child M, Bedford W; et al. (2014). “The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor”. Antivir Ther. doi:10.3851/IMP2773. PMID 24704773.
↑ Lawitz E, Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Bhanja S; et al. (2013). “A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment”. J Hepatol. 59 (1): 11–7. doi:10.1016/j.jhep.2013.02.008. PMID 23439259.
↑ Herbst DA, Reddy KR (2013). “NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection”. Expert Opin Investig Drugs. 22 (10): 1337–46. doi:10.1517/13543784.2013.826189. PMID 23931586.
↑ Pockros PJ, Jensen D, Tsai N, Taylor R, Ramji A, Cooper C; et al. (2013). “JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients”. Hepatology. 58 (2): 514–23. doi:10.1002/hep.26275. PMID 23359491.
↑ Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E; et al. (2014). “Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis”. N Engl J Med. 370 (20): 1879–88. doi:10.1056/NEJMoa1402355. PMID 24720702.
↑ Nishiguchi S, Sakai Y, Kuboki M, Tsunematsu S, Urano Y, Sakamoto W; et al. (2014). “Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection”. Liver Int. 34 (1): 78–88. doi:10.1111/liv.12254. PMID 23944720.

Template:WH Template:WS

[pmid23672640-1] Jiang Y, Andrews SW, Condroski KR, Buckman B, Serebryany V, Wenglowsky S; et al. (2014). “Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease”. J Med Chem. 57 (5): 1753–69. doi:10.1021/jm400164c. PMID 23672640.

[pmid24704773-2] Eley T, He B, Chang I, Colston E, Child M, Bedford W; et al. (2014). “The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor”. Antivir Ther. doi:10.3851/IMP2773. PMID 24704773.

[pmid23439259-3] Lawitz E, Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Bhanja S; et al. (2013). “A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment”. J Hepatol. 59 (1): 11–7. doi:10.1016/j.jhep.2013.02.008. PMID 23439259.

[pmid23931586-4] Herbst DA, Reddy KR (2013). “NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection”. Expert Opin Investig Drugs. 22 (10): 1337–46. doi:10.1517/13543784.2013.826189. PMID 23931586.

[pmid23359491-5] Pockros PJ, Jensen D, Tsai N, Taylor R, Ramji A, Cooper C; et al. (2013). “JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients”. Hepatology. 58 (2): 514–23. doi:10.1002/hep.26275. PMID 23359491.

[pmid24720702-6] Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E; et al. (2014). “Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis”. N Engl J Med. 370 (20): 1879–88. doi:10.1056/NEJMoa1402355. PMID 24720702.

[pmid23944720-7] Nishiguchi S, Sakai Y, Kuboki M, Tsunematsu S, Urano Y, Sakamoto W; et al. (2014). “Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection”. Liver Int. 34 (1): 78–88. doi:10.1111/liv.12254. PMID 23944720.

[1]

[2]

[3]

[4]

[5]

[6]

[7]